In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis

References

1. Boyle-Vavra S., Berke S. K., Lee J. C., Daum R. S. 2000; Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 44:272–277 [CrossRef]
   [Google Scholar]
2. British Society for Antimicrobial Chemotherapy; 2007; Methods for Antimicrobial Susceptibility Testing . Version 7 http://www.bsac.org.uk/susceptibility_testing/bsac_standardized_disc_susceptibility_method.cfm
3. Cui L., Ma X., Sato K., Okuma K., Tenover F. C., Mamizuka E. M., Gemmell C. G., Kim M.-N., Ploy M.-C. other authors 2003; Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus . J Clin Microbiol 41:5–14 [CrossRef]
   [Google Scholar]
4. Falagas M. E., Makris G. C., Dimopoulos G., Matthaiou D. K. 2008; Heteroresistance: a concern of increasing clinical significance?. Clin Microbiol Infect 14:101–104 [CrossRef]
   [Google Scholar]
5. Hayden M. K., Rezai K., Hayes R. A., Lolans K., Quinn J. P., Weinstein R. A. 2005; Development of daptomycin resistance in vivo in methicillin resistant Staphylococcus aureus . J Clin Microbiol 43:5285–5287 [CrossRef]
   [Google Scholar]
6. Jones T., Yeaman M. R., Sakoulas G., Yang S. J., Proctor R. A. 2008; Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry and drug binding. Antimicrob Agents Chemother 52:269–278 [CrossRef]
   [Google Scholar]
7. Murchan S., Kaufmann M. E., Deplano A., de Ryck R., Struelens M., Zinn C. E., Fussing V., Salmenlinna S., Vuopio-Varkila J. other authors 2003; Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus : a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol 41:1574–1585 [CrossRef]
   [Google Scholar]
8. Neoh H. M., Cui L., Yuzawa H., Takeuchi F., Matsuo M., Hiramatsu K. 2008; Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother 52:45–53 [CrossRef]
   [Google Scholar]
9. Patel J. B., Jevitt L. A., Hageman J., McDonald L. C., Tenover F. C. 2006; An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus . Clin Infect Dis 42:1652–1653 [CrossRef]
   [Google Scholar]
10. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering R. C., Eliopoulos G. M. 2006; Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50:1581–1585 [CrossRef]
    [Google Scholar]
11. Sharma M., Riederer K., Chase P., Khatib R. 2008; High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 27:433–437 [CrossRef]
    [Google Scholar]
12. Silverman J. A., Perlmutter N. G., Shapiro H. M. 2003; Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus . Antimicrob Agents Chemother 47:2538–2544 [CrossRef]
    [Google Scholar]
13. Vikram H. R., Havill N. L., Koeth L. M., Boyce J. M. 2005; Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 43:5384–5387 [CrossRef]
    [Google Scholar]
14. Voss A., Mouton J. W., van Elzakker E. P., Hendrix R. G., Goessens W., Kluytmans J. A., Krabbe P. F., de Neeling H. J., Sloos J. H. other authors 2007; A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). Ann Clin Microbiol Antimicrob 6:9 [CrossRef]
    [Google Scholar]
15. Wootton M., Howe R. A., Hillman R., Walsh T. R., Bennett P. M., MacGowan A. P. 2001; A modified population analysis profile method to detect Staphylococcus aureus with decreased susceptibilities to vancomycin in a UK hospital. J Antimicrob Chemother 47:399–404 [CrossRef]
    [Google Scholar]